한국발생생물학회지:발생과생식 (Development and Reproduction)

  • 제17권1호
  • /
  • Pages.1-8
  • /
  • 2013
  • /
  • 2465-9525(pISSN)
  • /
  • 2465-9541(eISSN)
한국발생생물학회 (The Korean Society of Developmental Biology)
권호 표지
DOI QR코드

DOI QR Code

Mammary Gland-Specific Expression of Biologically Active Human Osteoprotegerin in Transgenic Mice

  • Sung, Yoon-Young (Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine) ;
  • Lee, Chul-Sang (Department of Biology, Kunsan National University)
  • 투고 : 2012.12.28
  • 심사 : 2013.02.09
  • 발행 : 2013.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Osteoprotegerin (OPG) is a secreted glycoprotein that regulates bone resorption by inhibiting differentiation and activation of osteoclast, thereby potentially useful for the treatment of many bone diseases associated with increased bone loss. In this study, we designed a novel cDNA expression cassette by modifying the potent and mammary gland-specific goat ${\beta}$-casein/hGH hybrid gene construct and examined human OPG (hOPG) cDNA expression in transgenic mice. Six transgenic mice all successfully expressed hOPG in their milk at the level of 0.06-2,000 ${\mu}g/ml$. An estimated molecular weight of the milk hOPG was 55 kDa in SDS-PAGE, which is the same as a naturally glycosylated monomer. This hOPG expression was highly specific to the mammary glands of transgenic mice. hOPG mRNA was not detected in any organs analyzed except mammary gland. Functional integrity of milk hOPG was evaluated by TRAP (tartrate-resistant acid phosphatase) activity assay in bone marrow cell cultures. OPG ligand (OPG-L) treatment increased TRAP activity by two fold but it was completely abolished by co-treatment with transgenic milk containing hOPG. Taken together, our novel cDNA expression cassette could direct an efficient expression of biologically active hOPG, a potential candidate pharmaceutical for bone diseases, only in the mammary gland of transgenic mice.

키워드

과제정보

연구 과제 주관 기관 : Kunsan National University

참고문헌

  1. Akers RM, McFadden TB, Beal WE, Guidry AJ, Farrell HM (1986) Radioimmunoassay for measurement of bovine alpha-lactalbumin in serum, milk and tissue culture media. J Dairy Res 53:419-429. https://doi.org/10.1017/S0022029900025036
  2. Anandarajah AP (2009) Role of RANKL in bone diseases. Trends Endocrinol Metab 20:88-94. https://doi.org/10.1016/j.tem.2008.10.007
  3. Dyck MK, Lacroix D, Pothier F, Sirard MA (2003) Making recombinant proteins in animals-different systems, different applications. Trends Biotechnol 21:394-399. https://doi.org/10.1016/S0167-7799(03)00190-2
  4. Echelard Y, Ziome C, Meade H (2006) Production of recombinant therapeutic proteins in the milk of transgenic animals. BioPharm Int 2:1-6.
  5. Filgueira L (2010) Osteoclast differentiation and function. In: Heymann D (ed.), Bone Cancer. Academic Press, pp 59-66.
  6. Grabowski H, Le Bars D, Chene N, Attal J, Malienou- Ngassa R, Puissant C, Houdebine LM (1991) Rabbit whey acidic protein concentration in milk, serum, mammary gland extract, and culture medium. J Dairy Sci 74:4143-4150. https://doi.org/10.3168/jds.S0022-0302(91)78609-8
  7. Heymann D (2012) Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol 1:2-11. https://doi.org/10.1016/j.jbo.2012.03.001
  8. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625. https://doi.org/10.1016/j.coph.2005.06.005
  9. Kues WA, Niemann H (2011) Advances in farm animal transgenesis. Prev Vet Med 102:146-156. https://doi.org/10.1016/j.prevetmed.2011.04.009
  10. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435-448. https://doi.org/10.1016/S0002-9440(10)64556-7
  11. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176. https://doi.org/10.1016/S0092-8674(00)81569-X
  12. Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Redini F (2010) Regulation of osteoprotegerin proor anti-tumoral activity by bone tumor microenvironment. Lamoureux F et al. Biochim Biophys Acta. 1805:17-24.
  13. Lee CS (2006) Goat $\beta$-casein promoter directs hGH expression at a high level and in a mammary-specific manner in transgenic mice. Korean J Genetics 28:131-137.
  14. Liu JZ, Hu YY, Ji ZL, Chen SM (2003) Expression of human osteoprotegerin gene in E. coli and bioactivity analysis of expression product (Article in Chinese) Zhonghua Wai Ke Za Zhi 41:641-645.
  15. Maga EA, Murray JD (1995) Mammary gland expression of transgenes and the potential for altering the properties of milk. Biotechnology (NY) 13:1452-1456. https://doi.org/10.1038/nbt1295-1452
  16. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474. https://doi.org/10.1084/jem.192.4.463
  17. Oh KB, Lee CS (2009) Characterization of double transgenic mice harboring both goat $\beta$-casein/hGH and goat $\beta$- casein/hG-CSF hybrid genes. Dev Reprod 13:191-198.
  18. Oh KB, Lee CS (2010) Co-expression of IRES-mediated hG-CSF cDNA and hGH gene under the control of goat $\beta$-casein promoter. Dev Reprod 14:13-19.
  19. Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, Brinster RL (1991) Helerologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 88:478-482. https://doi.org/10.1073/pnas.88.2.478
  20. Persuy MA, Legrain S, Printz C, Stinnakre MG, Lepourry L, Brignon G, Mercier JC (1995) High-level, stageand mammary-tissue-specific expression of a caprine kappa-casein-encoding minigene driven by a beta-casein promoter in transgenic mice. Gene 165:291-296. https://doi.org/10.1016/0378-1119(95)00405-U
  21. Reid P, Holen I (2009) Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 88:1-17.
  22. Ross FP (2006) Osteoclast biology and bone resorption. In: Murray FJ (ed.), Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. American Society for Bone and Mineral Research Publication Office, Durham, pp 30-35.
  23. Rudolph NS (1999) Biopharmaceutical production in transgenic livestock. Trends Biotechnol 17:367-374. https://doi.org/10.1016/S0167-7799(99)01341-4
  24. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Program AE, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319. https://doi.org/10.1016/S0092-8674(00)80209-3
  25. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142. https://doi.org/10.1006/bbrc.1997.6603
  26. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484. https://doi.org/10.1210/endo.141.9.7634
  27. Wan M, Shi X, Feng X, Cao X (2001) Transcroptional mechanisms of bone morphogenetic protein-induced osteoprotegerin gene expression. J Biol Biochem 276: 10119-10125.
  28. Yan JB, Wang S, Huang WY, Xiao YP, Ren ZR, Huang SZ, Zeng YT (2006) Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity. Biochem Genet 44:349-360.
  29. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602. https://doi.org/10.1073/pnas.95.7.3597